ArticleFrontiers in immunology2025
Study of the interaction between cardiometabolic index and inflammatory index on the risk of prostate cancer development.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Combined Pharmacologic and Nutritional Modulation of High-Fat Diet-Associated Tumor-Supportive Features in Prostate Cancer Models.Biomolecules · 2026Article
- Higher cardiometabolic index elevates the risk of hyperuricemia in the elderly: findings from the China health and retirement longitudinal study.Annals of medicine · 2025Article
- Association of cardiometabolic index and glomerular filtration rate with sleep disorders: NHANES 2005-2020.Journal of health, population, and nutrition · 2025Article
- Inflammatory index-based nomogram for risk stratification of erectile dysfunction: a cross-sectional study with dual-cohort validation and mendelian randomization analysis.Translational andrology and urology · 2025Article
- Association of systemic inflammatory biomarkers with prostate cancer risk: a population-based (NHANES) and clinical validation study.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer (PCa) is an important cause of fatality in older men, with inflammation and metabolic disorders as risk factors for PCa. This study examined how systemic inflammation, measured by inflammatory indices, interacts with the cardiometabolic index (CMI), a marker of obesity and dyslipidemia, to influence the risk of developing PCa. Methods: This study consisted of 1,591 male patients recruited from the Department of Urology at the First Affiliated Hospital of Xinjiang Medical University between 2022 and 2024. Propensity score matching was employed to adjust the sample size, resulting in a final cohort of 149 PCa patients and 296 matched controls. Logistic regression models and restricted cubic spline (RCS) analyses were employed to evaluate the associations between CMI and various inflammatory indices (e.g., PIV, SIRI, PLR, NLR, LMR) with prostate cancer. Interaction tests were conducted to investigate the impact of the interplay between inflammatory indices and CMI on the risk of prostate cancer. Results: NLR, PLR, PIV, and SIRI were significantly positively associated with prostate cancer (PCa) risk, whereas LMR exhibited a significant negative association. The CMI was significantly associated with an elevated risk of prostate cancer (PCa) (OR = 1.97, 95% CI: 1.38~2.81). Restricted cubic spline (RCS) analysis revealed a nonlinear dose-response relationship between CMI and prostate cancer (PCa) risk, with the risk plateauing at CMI ≈ 0.65. Sensitivity analyses confirmed the robustness of these results. Significant interactions were observed between CMI and inflammatory indices, particularly NLR, PLR, and LMR, suggesting synergistic effects on prostate cancer (PCa) risk. Conclusions: The present study demonstrated that inflammation indicators and CMI exhibited a strong association with the risk of PCa. Furthermore, a significant interaction was observed between CMI and inflammation indicators. These findings provide a novel perspective for PCa risk prediction and prevention, suggesting that inflammation and metabolic status should be considered together when assessing PCa risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.